Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading on Nasdaq under the ticker LGST, is a clinical-stage biopharmaceutical company focused on proprietary T-cell receptor-based immunotherapies targeting infectious diseases and oncology. The company completed its SPAC business combination and began operating as a public entity in 2023, filing a Form 10-Q with the SEC on November 13, 2023, covering its early post-merger operating period. Tevogen Bio operates in the healthcare and biotechnology sector, with its pipeline centered on precision immunology platforms. To access full filing history, deal timelines, and SPAC analytics for LGST and hundreds of other transactions, sign up for a free account at SpacDesk.